The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 15 of the 23 sources its claims cite were checked for support.
Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice
Open accessAbstract
Mitochondrial dysfunction is one of the possible mechanisms by which azole resistance can occur in Candida glabrata. Cells with mitochondrial DNA deficiency (so-called "petite mutants") upregulate ATP binding cassette (ABC) transporter genes and thus display increased resistance to azoles. Isolation of such C. glabrata mutants from patients receiving antifungal therapy or prophylaxis has been rarely reported. In this study, we characterized two sequential and related C. glabrata isolates recovered from the same patient undergoing azole therapy. The first isolate (BPY40) was azole susceptible (fluconazole MIC, 4 μg/ml), and the second (BPY41) was azole resistant (fluconazole MIC, >256 μg/ml). BPY41 exhibited mitochondrial dysfunction and upregulation of the ABC transporter genes C. glabrata CDR1 (CgCDR1), CgCDR2, and CgSNQ2. We next assessed whether mitochondrial dysfunction conferred a selective advantage during host infection by testing the virulence of BPY40 and BPY41 in mice. Surprisingly, even with in vitro growth deficiency compared to BPY40, BPY41 was more virulent (as judged by mortality and fungal tissue burden) than BPY40 in both systemic and vaginal murine infection models. The increased virulence of the petite mutant correlated with a drastic gain of fitness in mice compared to that of its parental isolate. To understand this unexpected feature, genome-wide changes in gene expression driven by the petite mutation were analyzed by use of microarrays during in vitro growth. Enrichment of specific biological processes (oxido-reductive metabolism and the stress response) was observed in BPY41, all of which was consistent with mitochondrial dysfunction. Finally, some genes involved in cell wall remodelling were upregulated in BPY41 compared to BPY40, which may partially explain the enhanced virulence of BPY41. In conclusion, this study shows for the first time that mitochondrial dysfunction selected in vivo under azole therapy, even if strongly affecting in vitro growth characteristics, can confer a selective advantage under host conditions, allowing the C. glabrata mutant to be more virulent than wild-type isolates.
Overview
CoChat Summary
TL;DR
A clinical *Candida glabrata* petite mutant (BPY41) that arose after azole therapy was azole resistant and, despite in vitro growth deficiency, was more virulent and fitter than its azole-susceptible parent (BPY40) in murine systemic and rat vaginal infection models. An in vitro-generated petite mutant (DSY4339) did not show this enhanced virulence, suggesting the origin/selection context of mitochondrial dysfunction matters.
Key findings
- BPY41 was azole resistant (fluconazole MIC >256 μg/ml) versus BPY40 (fluconazole MIC 4 μg/ml), with cross-resistance to itraconazole and voriconazole, and overexpressed *CgCDR1*, *CgCDR2*, *CgSNQ2*, and *CgPDR1* without a detected *CgPDR1* mutation.
- BPY41 showed mitochondrial dysfunction: no growth on glycerol, absent SYTO18 mitochondrial staining, no recoverable mitochondrial DNA, and strongly reduced oxygen consumption.
- BPY41 was more virulent than BPY40 in mice: lower LD50s (BPY41 3.45 × 10^7 CFU immunocompetent and 2.3 × 10^7 CFU immunosuppressed vs. BPY40 7.2 × 10^7 and 6.8 × 10^7 CFU), higher tissue burdens in kidney, spleen, and liver at day 7, and slower vaginal clearance in rats.
- The in vitro-generated petite DSY4339 had higher LD50s (2.81 × 10^8 CFU immunocompetent and 1.65 × 10^8 CFU immunosuppressed) and lowest tissue burdens, with virulence not significantly different from BPY40.
Methods
- Two sequential related clinical *C. glabrata* isolates from the same patient were studied: BPY40 (azole-susceptible parent) and BPY41 (azole-resistant petite mutant); DSY4339 was generated in vitro from BPY40 by ethidium bromide exposure.
- Murine systemic infection models used female BALB/c mice for survival, LD50 determination, and tissue burden (liver, spleen, kidney); a rat vaginal mucosa infection model used oophorectomized female Wistar rats. In vitro and in vivo fitness competitions mixed BPY40 and BPY41 and distinguished them by growth on fluconazole.
- Genome-wide expression was analyzed by custom *C. glabrata* Agilent microarrays with three biological replicates; genes were included if expression changed at least 2-fold between BPY41 and BPY40 in at least two independent experiments with corrected *P* < 0.05. qRT-PCR measured *CgCDR1*, *CgCDR2*, *CgSNQ2*, *CgPDR1*, and *CgYPS*.
Limitations
- The paper states it cannot exclude that the in vitro- or in vivo-generated mitochondrial mutants also contain nuclear mutations that decrease or increase virulence, respectively.
- The paper notes that the exact regulatory mechanisms behind ABC transporter upregulation in petite mutants remain largely unresolved.
- The provided text is truncated in the Results, so later analyses and the full discussion are not available here; the paper’s statement beginning “Our current data cannot confirm…” is cut off.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 1 Not valid · 5 Not checked · 18 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“upregulation of the ABC transporter genes *C. glabrata CDR1* (*CgCDR1*), *CgCDR2*, and *CgSNQ2*”
§ Loss of Mitochondrial Functions Associated with Azole Resistance in *Candida glabrata* Results in Enhanced Virulence in Mice[▿](#FN2),[†](#FN1) > Abstract
What the sources say
- Could not verifycites [14] sourceExperimental — accuracy not yet measured
The Results section on ABC-transporter expression reports that CgCDR1, CgCDR2, and CgSNQ2 are not always upregulated together. Searches for BPY41 and for BPY41 with the three gene names found no passage reporting its expression profile; the passage about BPY55 concerns a different strain. (LLM, conf=0.72)
- Not checked — no full text of the sourcecites [35] source
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“BPY41 exhibited mitochondrial dysfunction”
- Also stated in: § Characteristics of BPY41, a clinical petite mutant isolate. · plain
“BPY41 exhibited typical features of a petite phenotype, including the absence of growth in glycerol-containing medium and absence of mitochondrial staining with SYTO18 ([14](#B14)).”
§ Loss of Mitochondrial Functions Associated with Azole Resistance in *Candida glabrata* Results in Enhanced Virulence in Mice[▿](#FN2),[†](#FN1) > Abstract
What the sources say
- Supportedcites [14] source
The Results section, “Isolation and Characterization of CgPDR1 Alleles from C. glabrata Clinical Isolates,” identifies BPY41 as having altered mitochondrial respiratory capacity, based on its inability to grow on glycerol as the sole carbon source and defects in mitochondrial DNA. This supports the paraphrase that BPY41 exhibited mitochondrial dysfunction. (LLM, conf=0.94)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Characteristics of BPY41, a clinical petite mutant isolate. · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, *C. glabrata* can develop azole resistance at a relatively high frequency ([33](#B33)).”
§ Loss of Mitochondrial Functions Associated with Azole Resistance in *Candida glabrata* Results in Enhanced Virulence in Mice[▿](#FN2),[†](#FN1) > INTRODUCTION
What the sources say
- Supportedcites [33] source
The Results report that azole-susceptible C. glabrata generated fluconazole-resistant cells in vitro at frequencies of 2 × 10−4 to 4 × 10−4. The paper describes this as high-frequency azole resistance, supporting the claim that the yeast can develop azole resistance at a relatively high frequency. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Remarkably, loss of mitochondrial function in *C. glabrata* is associated with acquisition of azole resistance ([33](#B33)).”
§ Loss of Mitochondrial Functions Associated with Azole Resistance in *Candida glabrata* Results in Enhanced Virulence in Mice[▿](#FN2),[†](#FN1) > INTRODUCTION
What the sources say
- Supportedcites [33] source
The Discussion explicitly links loss of mitochondrial function in C. glabrata to acquisition of azole resistance. The Abstract likewise reports that high-frequency azole resistance acquired in vitro was linked to mitochondrial loss. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, no *CgPDR1* mutation was detected in BPY41 ([14](#B14)).”
§ Loss of Mitochondrial Functions Associated with Azole Resistance in *Candida glabrata* Results in Enhanced Virulence in Mice[▿](#FN2),[†](#FN1) > RESULTS > Characteristics of BPY41, a clinical petite mutant isolate.
What the sources say
- Supportedcites [14] source
In Results, under “Isolation and Characterization of CgPDR1 Alleles from C. glabrata Clinical Isolates” (page not provided), BPY41 is listed among the azole-resistant isolates that were exceptions to the observed occurrence of CgPDR1 mutations. (LLM, conf=0.93)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
18 more claims · 1 with their cited sources checked
Create a free account to see all 36 claims and every source verdict.
- Probably not a substantial claim. 9
- It may state two separate claims as one. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apparently, the inactivation of these metabolic signaling pathways promotes survival during resistance evolution in both species (22).”
From Divergent mitochondrial responses and metabolic signal pathways secure the azole resistance in Crabtree-positive and negative Candida species (2024) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The virulent analyses, based on mortality and fungal tissue burden in both systemic and vaginal murine infection models, suggested higher virulence of BPY41 than BPY40.”
From Candida glabrata: pathogenicity and resistance mechanisms for adaptation and survival (2021) · cites this paper as [93]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An association of decreased fluconazole susceptibility with mitochondrial dysfunction in C. glabrata has been reported by several laboratories (7–12).”
From Azole Susceptibility and Transcriptome Profiling in Candida albicans Mitochondrial Electron Transport Chain Complex I Mutants (2013) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Mitochondrial dysfunction in pathogenic fungi or model yeast causes altered susceptibilities to antifungal drugs.”
From Azole Susceptibility and Transcriptome Profiling in Candida albicans Mitochondrial Electron Transport Chain Complex I Mutants (2013) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Ferrari et al. (9) demonstrated that a mitochondrial deficiency in C. glabrata strain BPY41 caused resistance to azoles associated with the upregulation of ABC transporter genes CgCDR1, CgCDR2, and CgSNQ2.”
From Azole Susceptibility and Transcriptome Profiling in Candida albicans Mitochondrial Electron Transport Chain Complex I Mutants (2013) · cites this paper as [9]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Dujon, B., Sherman, D., Fischer, G., Durrens, P., Casaregola, S., Lafontaine, I., de Montigny, J., Marck, C., Neuvéglise, C., Talla, E., et al. (2004) · Nature · doi:10.1038/nature02579 · Cited by 1,623
Changing epidemiology of systemic fungal infections
Richardson, M., & Lass-Flörl, C. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01978.x · Cited by 524
The biological cost of mutational antibiotic resistance: any practical conclusions?
Andersson, D. I. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.07.002 · Cited by 472
Sanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337
Self-citationSanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319
Self-citationFerrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000268 · Cited by 295
Self-citationKaur, R., Ma, B., & Cormack, B. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611195104 · Cited by 284
RSAT: regulatory sequence analysis tools
Thomas-Chollier, M., Sand, O., Turatsinze, J.-V., Janky, R., Defrance, M., Vervisch, E., Brohee, S., & van Helden, J. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn304 · Cited by 278
Genome microarray analysis of transcriptional activation in multidrug resistance yeast mutants
DeRisi, J., van den Hazel, B., Marc, P., Balzi, E., Brown, P., Jacq, C., & Goffeau, A. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01294-1 · Cited by 276
Sanglard, D., Ischer, F., & Bille, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1174-1183.2001 · Cited by 247
Self-citation
Cited by
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“This mutant phenotype has been recovered clinically (Bouchara et al., 2000; Ferrari et al., 2011), but is not common among clinical isolates.”
BackgroundInfluentialAntifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
“glabrata, as well as loss of mitochondrial functions, not only mediate antifungal (azole) resistance but also enhance virulence in animal models [41–43].”
BackgroundMechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
Self-citationCandida glabrata: A review of its features and resistance
Rodrigues, C. F., Silva, S., & Henriques, M. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2009-3 · Cited by 268
Metadata
- Authors
- Ferrari, S., Sanguinetti, M., De Bernardis, F., Torelli, R., Posteraro, B., Vandeputte, P., & Sanglard, D.
- Affiliations
- University of Lausanne (CH)
- Università Cattolica del Sacro Cuore (IT)
- Department of Infectious, Parasitic, and Immune-Mediated Diseases, Istituto Superiore di Sanità, Rome, Italy
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-05
- Volume
- 55
- Issue
- 5
- Pages
- 1852-1860
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3088236
- OpenAlex
- W2098964280
- Semantic Scholar
- 8b330e8c08f4c329027f81adbc47ae8af0f15169
- Cited by
- 144
- References
- 44
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 12 · 2023: 10 · 2022: 8 · 2021: 7 · 2020: 9 · 2019: 12 · 2018: 12 · 2017: 12 · 2016: 5 · 2015: 5 · 2014: 9 · 2013: 12 · 2012: 12
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- Candida glabrata, azole resistance, mitochondrial dysfunction, petite mutants, ABC transporters, CDR1, CDR2, fluconazole, fungal virulence, antifungal therapy, cell wall remodeling, oxidative stress response, gene expression profiling, fitness cost
- MeSH terms
- Animals, Azoles, Female, Mice, Inbred BALB C, Microbial Sensitivity Tests, Molecular Sequence Data, Virulence, Gene Expression Regulation, Fungal, Computational Biology, Reverse Transcriptase Polymerase Chain Reaction, Drug Resistance, Fungal, Candida glabrata, Microarray Analysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice. https://app.cochat.ai/papers/10.1128/aac.01271-10
- The paper
- Ferrari, S., Sanguinetti, M., De Bernardis, F., Torelli, R., Posteraro, B., Vandeputte, P., & Sanglard, D. (2011). Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01271-10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.